ArticleNature2020
Activation of the GLP-1 receptor by a non-peptidic agonist.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 1 pooled it
10.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it, 167 citations in OpenAlex.
- GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification.Nature genetics · 2023Pooled it
- Effects of GLP-1 and GIP on Islet Function in Glucose-Intolerant, Pancreatic-Insufficient Cystic Fibrosis.Diabetes · 2022Trial
- Structural basis for small-molecule agonism at GCGR and GIPR via a conserved intracellular allosteric site.Acta pharmacologica Sinica · 2026Article
- Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists.Vision (Basel, Switzerland) · 2026Review
- Discovery and optimization of novel indolecarboxylic acid derivative as potent glucagon-like peptide‑1 receptor agonists.Molecular diversity · 2026Article
- Citrus Changshan Huyou extracts as natural GLP-1R agonists attenuate atherosclerosis via the GLP-1R/PKA/CREB pathway: a functional food perspective.Frontiers in nutrition · 2026Article
- An Insight into Pharmaceutical Design and Pharmacokinetic Characteristics of GLP-1 RAs.Current pharmaceutical design · 2026Review
- Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine.Frontiers in pharmacology · 2026Review
- Protein-Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection.Molecules (Basel, Switzerland) · 2025Review
- Small-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach.Medicina (Kaunas, Lithuania) · 2025Review
- Structure-Based Discovery of Orthosteric Non-Peptide GLP-1R Agonists via Integrated Virtual Screening and Molecular Dynamics.International journal of molecular sciences · 2025Article
- DiffMC-Gen: A Dual Denoising Diffusion Model for Multi-Conditional Molecular Generation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Hidden GPCR structural transitions addressed by multiple walker supervised molecular dynamics (mwSuMD).eLife · 2025Article
- Ligand-Induced Biased Activation of GPCRs: Recent Advances and New Directions from In Silico Approaches.Molecules (Basel, Switzerland) · 2025Review
- The therapeutic effects and mechanisms of glucagon-like peptide-1 receptor agonists in neurocognitive disorders.Therapeutic advances in neurological disorders · 2025Review
- Design, Structure-Activity Relationships, and Computational Modeling Studies of a Series of α-Helix Biased, Ultra-Short Glucagon-like Peptide-1 Receptor Agonists.Molecules (Basel, Switzerland) · 2024Article
- Article
- Review
- G Protein-Coupled Receptors: A Century of Research and Discovery.Circulation research · 2024Review
- Cryo-electron microscopy for GPCR research and drug discovery in endocrinology and metabolism.Nature reviews. Endocrinology · 2024Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
20 authors at 8 institutions in 5 countries.
Peishen Zhao *Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Yi-Lynn Liang *Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Matthew J Belousoff *Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Giuseppe Deganutti *School of Biological Sciences, University of Essex, Colchester, UK.
Madeleine M FletcherDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Francis S WillardLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
Michael G BellLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
Michael E ChristeLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
Kyle W SloopLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
Asuka InoueGraduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan.
Tin T TruongDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Lachlan ClydesdaleDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Sebastian G B FurnessDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Arthur ChristopoulosDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Ming-Wei WangThe National Center for Drug Screening and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Laurence J MillerMayo Clinic, Scottsdale, AZ, USA.
Christopher A ReynoldsSchool of Biological Sciences, University of Essex, Colchester, UK.
Radostin DanevGraduate School of Medicine, University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan. rado@m.u-tokyo.ac.jp.
Patrick M SextonDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. patrick.sexton@monash.edu.
Denise WoottenDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. denise.wootten@monash.edu.
Monash University · AUEli Lilly (United States) · USFudan University · CNUniversity of Essex · GBMayo Clinic in Arizona · USNational Center for Drug Screening · CNThe University of Tokyo · JPTohoku University · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
Class B G-protein-coupled receptors are major targets for the treatment of chronic diseases, including diabetes and obesity
Indexed as
Glucagon-Like Peptide-1 Receptor AgonistsAnimalsCHO CellsCricetinaeCricetulusGlucagon-Like Peptide-1 ReceptorHumansIsoquinolinesKineticsModels, MolecularPhenylalanineProtein Structure, QuaternaryProtein Structure, TertiaryPyridinesStructural Homology, ProteinGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsIsoquinolinesPhenylalaninePyridinesTT-OAD2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.